Arax Advisory Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$89.6K Buy
4,179
+4,028
+2,668% +$61.7K ﹤0.01% 2820
2026
Q1
$2.1K Sell
151
-64
-30% -$1.02K ﹤0.01% 3097
2025
Q4
$3.49K Sell
215
-3,941
-95% -$64.3K ﹤0.01% 3029
2025
Q3
$62.2K Buy
+4,156
New +$50.6K ﹤0.01% 1729
2024
Q4
Sell
-97
Closed -$497 2419
2024
Q3
$497 Hold
97
﹤0.01% 2404
2024
Q2
$352 Buy
+97
New +$308 ﹤0.01% 2376

Other funds holding ADPT

Arax Advisory Partners's ADPT Position: Q2 2026 in Review

Arax Advisory Partners increased its Adaptive Biotechnologies (ADPT) stake by 2,668% in Q2 2026, buying an estimated $61.7K and bringing the position to 4,179 shares worth $89.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2820.

Arax Advisory Partners first reported a position in ADPT in Q2 2024 and has held it in 6 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Arax Advisory Partners held 4,179 shares of Adaptive Biotechnologies worth $89.6K as of Q2 2026.
  • Arax Advisory Partners bought 4,028 Adaptive Biotechnologies shares in Q2 2026, an estimated $61.7K.
  • Adaptive Biotechnologies made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2820 holding.
  • Arax Advisory Partners first reported a position in Adaptive Biotechnologies in Q2 2024 and has held it in 6 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.